As of December 31, 2024, Orgenesis, Inc. carries a market capitalization of 9.77M, placing it among publicly traded companies globally. Its enterprise value stands at 27.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.77M |
| Enterprise Value | 27.92M |
Orgenesis, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.
| Earnings Date | 11/16/2026 |
As of December 31, 2024, Orgenesis, Inc. has 5.17M shares outstanding.
| Shares Outstanding | 5.17M |
These figures are as of December 31, 2024. The price-to-sales ratio is 7.80, and the price-to-book ratio stands at -0.26.
| PS Ratio | 7.80 |
| PB Ratio | -0.26 |
| P/TBV Ratio | -0.26 |
| P/FCF Ratio | -0.47 |
| P/OCF Ratio | -0.47 |
These figures are as of December 31, 2024. The EV/Sales ratio of 26.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 27.92M versus a market cap of 9.77M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 26.98 |
As of December 31, 2024, Orgenesis, Inc. maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -48.65, indicating conservative leverage, while an interest coverage ratio of -7.81 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.03 |
| Quick Ratio | 0.01 |
| Debt / Equity | -48.65 |
| Debt / EBITDA | -0.63 |
| Interest Coverage | -7.81 |
These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -605.73, reflecting losses generated across the asset base. The company generates approximately 8,038.83 in revenue per employee across its workforce of 128.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 559.24 indicates how many times Orgenesis, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -605.73 |
| Revenue Per Employee | 8,038.83 |
| Employee Count | 128.75 |
| Inventory Turnover | 559.24 |
Over the twelve months ended December 31, 2024, Orgenesis, Inc. recorded 97,000.00 in income tax expense. The company reported a pretax loss of -48.92M and -48.16M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 97,000.00 |
As of the close on November 16, 2026, Orgenesis, Inc.'s stock has gained approximately 57.14% over the past 52 weeks. The 50-day moving average sits at 0.34, while the 200-day moving average is 0.36.
| 52-Week Price Change | 57.14% |
| 50-Day Moving Average | 0.34 |
| 200-Day Moving Average | 0.36 |
Over the twelve months ended December 31, 2024, Orgenesis, Inc. generated 1.04M in revenue and converted that into -48.16M in net income, yielding earnings per share of -11.47. EBITDA reached -29.18M, while operating income came in at -29.29M.
| Revenue | 1.04M |
| Gross Profit | -8.47M |
| Operating Income | -29.29M |
| Pretax Income | -48.92M |
| Net Income | -48.16M |
| EBITDA | -29.18M |
| EBIT | -31.27M |
| Earnings Per Share (EPS) | -11.47 |
As of December 31, 2024, Orgenesis, Inc. holds 78,000.00 in cash and equivalents against 18.26M in total debt, resulting in a net debt position of 16.61M. Total book value stands at -37.50M, with working capital of -26.16M providing operational flexibility.
| Cash & Cash Equivalents | 78,000.00 |
| Total Debt | 18.26M |
| Net Debt | 16.61M |
| Equity (Book Value) | -37.50M |
| Book Value Per Share | -7.25 |
| Working Capital | -26.16M |
Orgenesis, Inc. produced -17.08M in operating cash flow over the twelve months ended December 31, 2024. After subtracting -263,000.00 in capital expenditures, free cash flow totaled -17.34M - equivalent to -4.06 per share.
| Operating Cash Flow | -17.08M |
| Capital Expenditures | -263,000.00 |
| Free Cash Flow | -17.34M |
| FCF Per Share | -4.06 |
Over the twelve months ended December 31, 2024, Orgenesis, Inc. posted a gross margin of -818.55, reflecting its pricing power and cost economics. The operating margin of -2,829.95 and net profit margin of -4,653.62 provide insight into operational efficiency.
| Gross Margin | -818.55 |
| Operating Margin | -2,829.95 |
| Pretax Margin | -4,726.18 |
| Profit Margin | -4,653.62 |
| EBITDA Margin | -2,819.32 |
These figures cover the twelve months ended December 31, 2024. Free cash flow yield is negative at -214.72: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -163.28, meaning Orgenesis, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -163.28 |
| FCF Yield | -214.72 |
Orgenesis, Inc.'s most recent stock split took place on September 25, 2024 with a 10:1 split ratio.
| Last Split Date | 9/25/2024 |
| Split Ratio | 10:1 |
As of December 31, 2024, Orgenesis, Inc. has an Altman Z-Score of -326.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -326.80 |